Is CRISPR Therapeutics AG (CRSP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.8% / 30% | 36.4% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 3.8% / 33% | 36.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 9.1% / 33% | 87.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 3.8% / 33% | 36.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 9.1% / 33% | 87.2% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -17912.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -30.2% | |
| Return on Assets (ROA) | -15.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$345M |
| Free Cash Flow | -$371M |
| Total Debt | $207M |
| Debt-to-Equity | 10.8 |
| Current Ratio | 13.3 |
| Total Assets | $2.3B |
Price & Trading
| Last Close | $47.55 |
| 50-Day MA | $52.44 |
| 200-Day MA | $56.07 |
| Avg Volume | 1.9M |
| Beta | 1.7 |
|
52-Week Range
$30.04
| |
About CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CRISPR Therapeutics AG (CRSP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CRISPR Therapeutics AG is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CRISPR Therapeutics AG's debt ratio?
CRISPR Therapeutics AG's debt ratio is 3.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 9.1%.
What are CRISPR Therapeutics AG's key financial metrics?
CRISPR Therapeutics AG has a market capitalization of $4.4B. Return on equity stands at -30.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.